Brief: Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease
04/02/2026 13:40
Feb 4 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASE SAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026 SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026 Source text: ID:nBwb0FcTja Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure